Wedbush initiated coverage on Dianthus Therapeutics Inc DNTH, noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the complement C1s protein.
The analyst notes that the first-generation complement inhibitors validate complement as a viable drug target but leave the door open for improvements.
With DNTH103 advancing in multiple Phase 2 studies and preliminary Phase 1 data demonstrating a meaningful extension of half-life, Wedbush sees the generalized myasthenia gravis (gMG) opportunity as most attractive.
Wedbush initiates with an Outperform rating and a price target of $23.
- Massive Demand & Disruptive Potential – Boxabl has received interest for over 190,000 homes, positioning itself as a major disruptor in the housing market.
- Revolutionary Manufacturing Approach – Inspired by Henry Ford’s assembly line, Boxabl’s foldable tiny homes are designed for high-efficiency production, making homeownership more accessible.
- Affordable Investment Opportunity – With homes priced at $60,000, Boxabl is raising $1 billion to scale production, offering investors a chance to own a stake in its growth.
Recent Chronic inflammatory demyelinating polyneuropathy data from Argenx SE's ARGX nierengarten and Sanofi SA SNY also supports the use of a complement-inhibition approach in CIDP, but Wedbush leaves this indication as upside to DNTH estimates.
The analyst notes that complement inhibition remains a sought-after development area and sees DNTH103 as a promising candidate.
Acknowledging the dysregulated complement pathway's role in autoimmune diseases has made it a highly sought-after target in the pharmaceutical industry. The field remains intensely active, with three acquisitions of complement-focused public companies occurring in the last three years.
Complement inhibition continues to be regarded as a "hot" therapeutic area due to its potential in addressing various autoimmune conditions and maintaining substantial market interest and investment.
Price Action: DNTH shares are up 1.14% at $11.50 on the last check Wednesday.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
